Atlas Trials

Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab

Clinical trial NCT03286114 · TERMINATED

Trial details

NCT number
NCT03286114
Sponsor
University of Michigan Rogel Cancer Center
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Myelodysplastic SyndromesAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Start date
2017-12-21
Primary completion
2020-10-22
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.